Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma ...Middle East

OSLO, Norway, Aug. 3, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R...

Read More Details
Finally We wish PressBee provided you with enough information of ( Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma )

Also on site :

• Kylie Jenner Stuns in Sultry Outfit Ahead of Exclusive Release
• Today's Wordle Hint, Answer for 1472 on Monday, June 30, 2025
• ‘BBQ Brawl’ Shocker: Who Went Home After the Campfire Cowboy Feast Challenge?